| Literature DB >> 34170408 |
Jorine A Vermaire1, Cornelis P J Raaijmakers1, Irma M Verdonck-de Leeuw2,3, Femke Jansen2, C René Leemans2,3, Chris H J Terhaard1, Caroline M Speksnijder4,5.
Abstract
PURPOSE: Before and after treatment for head and neck cancer (HNC), many patients have problems with mastication, swallowing, and salivary flow. The aim of this study was to investigate the association between objective test outcomes of mastication, swallowing, and salivary flow versus patient-reported outcomes (PROs) measuring mastication-, swallowing-, and salivary flow-related quality of life.Entities:
Keywords: 100-mL water swallow test; EORTC QLQ-H&N35; GRIX; Head and neck cancer; Mixing ability test; Objective versus subjective data; SWAL-QoL-NL; Salivary flow test
Mesh:
Year: 2021 PMID: 34170408 PMCID: PMC8550505 DOI: 10.1007/s00520-021-06368-6
Source DB: PubMed Journal: Support Care Cancer ISSN: 0941-4355 Impact factor: 3.603
Characteristics of patients with HNC
| MAT and WST | Salivary flow test | |||||||
|---|---|---|---|---|---|---|---|---|
| Characteristics | M0 ( | M3 ( | M6 ( | Repeated measurements M0, M3, and M6 ( | M0 ( | M3 ( | M6 ( | Repeated measurements M0, M3, and M6 ( |
| Age (median, IQR) | 64.0 (15.5) | 64.0 (13.8) | 63.5 (13.8) | 63.5 (14.0) | 61.8 (16.0) | 63.2 (15.0) | 62.1 (13.5) | 64.0 (11.0) |
| Sex | ||||||||
| Male | 77 (76.2%) | 72 (78.3%) | 69 (75%) | 49 (76.6%) | 34 (75.6%) | 55 (84.6%) | 45 (78.9%) | 15 (75.0%) |
| Female | 24 (23.8%) | 20 (21.7%) | 23 (25%) | 15 (23.4%) | 11 (24.4%) | 10 (15.4%) | 12 (21.1%) | 5 (25.0%) |
| Tumor site | ||||||||
| Oropharynx | 36 (35.6%) | 37 (40.2%) | 34 (37.0%) | 27 (42.2%) | 14 (31.1%) | 26 (40.0%) | 23 (40.4%) | 6 (30.0%) |
| Larynx | 29 (28.7%) | 24 (26.1%) | 25 (27.2%) | 16 (25.0%) | 15 (33.3%) | 18 (27.7%) | 14 (24.6%) | 6 (30.0%) |
| Oral cavity | 27 (26.7%) | 24 (26.1%) | 26 (28.3%) | 17 (26.6%) | 11 (24.4%) | 16 (24.6%) | 16 (28.1%) | 6 (30.0%) |
| Hypopharynx | 3 (3.0%) | 0 (0.0%) | 3 (3.3%) | 0 (0%) | 1 (2.2%) | 0 (0.0%) | 1 (1.8%) | 0 (0.0%) |
| Unknown primary | 6 (5.9%) | 7 (7.6%) | 4 (4.3%) | 4 (6.3%) | 4 (8.9%) | 5 (7.7%) | 3 (5.3%) | 2 (10.0%) |
| Tumor stage | ||||||||
| I | 27 (26.7%) | 22 (23.9%) | 24 (26.1%) | 16 (25.0%) | 16 (35.6%) | 16 (24.6%) | 15 (26.3%) | 6 (30.0%) |
| II | 20 (19.8%) | 17 (18.5%) | 20 (21.7%) | 15 (23.4%) | 8 (17.8%) | 15 (23.1%) | 12 (21.1%) | 3 (15.0%) |
| III | 13 (12.9%) | 13 (14.1%) | 12 (13.0%) | 6 (9.4%) | 3 (6.7%) | 7 (10.8%) | 5 (8.8%) | 2 (10.0%) |
| IV | 41 (40.6%) | 40 (43.5%) | 36 (39.1%) | 27 (42.2%) | 18 (40.0%) | 27 (41.5%) | 25 (43.9%) | 9 (45.0%) |
| Primary treatment | ||||||||
| RT | 44 (43.6%) | 42 (45.7%) | 41 (44.6%) | 30 (46.9%) | 21 (46.7%) | 31 (47.7%) | 24 (42.1%) | 8 (40.0%) |
| CRT | 27 (26.7%) | 25 (27.2%) | 23 (25.0%) | 18 (28.1%) | 12 (26.7%) | 17 (26.2%) | 16 (28.1%) | 7 (35.0%) |
| Surgery | 20 (19.8%) | 16 (17.4%) | 19 (20.7%) | 11 (17.2%) | 8 (17.8%) | 12 (18.5%) | 10 (17.5%) | 4 (20.0%) |
| Surgery with PO(C)RT | 10 (9.9%) | 9 (9.8%) | 9 (9.8%) | 5 (7.8%) | 4 (8.9%) | 5 (7.7%) | 7 (12.3%) | 1 (5.0%) |
M0 before treatment, M3 3 months after treatment, M6 6 months after treatment; CRT chemoradiation therapy, IQR interquartile range, PO(C)RT post-operative (chemo) radiation therapy, RT radiation therapy
Fig. 1Boxplots displaying all objective measurements at M0, M3, and M6 for the MAT (a), number of swallows on the WST (b), duration of swallowing on the WST (c), and total salivary flow (d), respectively
Spearman correlation coefficients of the MAT versus the EORTC QLQ-H&N35 and SWAL-QoL-NL
| MAT | M0 ( | M3 ( | M6 ( | |||
|---|---|---|---|---|---|---|
| Spearman’s ρ | Spearman’s ρ | Spearman’s ρ | ||||
| EORTC QLQ-H&N35 | ||||||
| Pain in mouth | 0.082 | 0.417 | 0.066 | 0.541 | − 0.014 | 0.896 |
| Trouble with social eating | 0.141 | 0.166 | 0.276 | 0.009* | 0.201 | 0.054 |
| Teeth | − 0.004 | 0.972 | 0.097 | 0.368 | 0.106 | 0.313 |
| Opening mouth | 0.026 | 0.803 | 0.211 | 0.048* | − 0.028 | 0.792 |
| Feeding tube | − 0.102 | 0.319 | 0.146 | 0.173 | − 0.040 | 0.703 |
| Weight loss | − 0.119 | 0.247 | − 0.004 | 0.968 | − 0.009 | 0.936 |
| Weight gain | 0.058 | 0.571 | 0.004 | 0.970 | 0.086 | 0.412 |
| SWAL-QoL-NL | ||||||
| Food selection | 0.347 | 0.001*† | 0.227 | 0.034* | 0.232 | 0.026* |
| Eating duration | 0.361 | < 0.001*† | 0.154 | 0.152 | 0.185 | 0.078 |
| Eating desire | 0.167 | 0.105 | 0.014 | 0.900 | 0.211 | 0.043* |
| Fear of eating | 0.336 | 0.001*† | 0.172 | 0.108 | 0.163 | 0.119 |
| Total score | 0.310 | 0.002*† | 0.165 | 0.124 | 0.222 | 0.033* |
M0 before treatment, M3 3 months after treatment, M6 6 months after treatment
*p ≤ 0.05
†p ≤ 0.004 (Bonferroni correction)
Fig. 2Scatterplots displaying the highest correlation for each objective measure; the eating duration on the SWAL-QoL-NL versus the MAT at M0 (a), the total score on the SWAL-QoL-NL questionnaire versus the number of swallows on the WST at M6 (b), and duration at M6 (c), and the xerostomia by day versus the total amount of saliva at M6 (d), respectively
Spearman correlation coefficients of the WST versus the EORTC QLQ-H&N35 and SWAL-QoL-NL
| WST | Number of swallows | Duration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M0 ( | M3 ( | M6 ( | M0 ( | M3 ( | M6 ( | |||||||
| Spearman’s ρ | Spearman’s ρ | Spearman’s ρ | Spearman’s ρ | Spearman’s ρ | Spearman’s ρ | |||||||
| EORTC QLQ-H&N35 | ||||||||||||
| Pain in mouth | 0.088 | 0.378 | 0.175 | 0.094 | − 0.009 | 0.936 | 0.125 | 0.205 | 0.253 | 0.015* | − 0.075 | 0.479 |
| Swallowing | 0.145 | 0.145 | 0.201 | 0.055 | 0.110 | 0.295 | 0.172 | 0.082 | 0.260 | 0.012* | 0.176 | 0.094 |
| Dry mouth | 0.052 | 0.603 | 0.053 | 0.616 | − 0.085 | 0.422 | 0.013 | 0.897 | 0.177 | 0.091 | − 0.022 | 0.832 |
| Coughing | − 0.018 | 0.859 | 0.035 | 0.741 | − 0.056 | 0.595 | 0.090 | 0.364 | 0.092 | 0.385 | 0.018 | 0.866 |
| SWAL-QoL-NL | ||||||||||||
| General burden | 0.175 | 0.084 | 0.156 | 0.135 | 0.083 | 0.430 | 0.026 | 0.806 | 0.205 | 0.049* | 0.162 | 0.123 |
| Food selection | 0.106 | 0.292 | 0.226 | 0.029* | 0.244 | 0.020* | 0.110 | 0.299 | 0.332 | 0.001*† | 0.265 | 0.011* |
| Symptoms | 0.248 | 0.013* | 0.172 | 0.101 | 0.142 | 0.179 | 0.138 | 0.193 | 0.268 | 0.010* | 0.255 | 0.015* |
| Total score | 0.201 | 0.046* | 0.238 | 0.023* | 0.335 | 0.001*† | 0.194 | 0.064 | 0.353 | 0.001*† | 0.398 | < 0.001*† |
M0, before treatment, M3, 3 months after treatment, M6, 6 months after treatment
*p ≤ 0.05
†p ≤ 0.006 (Bonferroni correction)
Spearman correlation coefficients of salivary flow versus the EORTC QLQ-H&N35 and GRIX
| Total salivary flow | M0 ( | M3 ( | M6 ( | |||
|---|---|---|---|---|---|---|
| Spearman’s ρ | Spearman’s ρ | Spearman’s ρ | ||||
| EORTC QLQ-H&N35 | ||||||
| Dry mouth | − 0.227 | 0.126 | − 0.339 | 0.004*† | − 0.279 | 0.031* |
| Sticky saliva | − 0.217 | 0.143 | − 0.321 | 0.006*† | − 0.350 | 0.006*† |
| GRIX | ||||||
| Xerostomia during day | − 0.254 | 0.092 | − 0.332 | 0.006*† | − 0.441 | 0.001*† |
| Xerostomia during night | − 0.147 | 0.329 | − 0.225 | 0.063 | − 0.099 | 0.450 |
| Xerostomia total score | − 0.182 | 0.232 | − 0.327 | 0.008* | − 0.320 | 0.015* |
| Sticky saliva during day | − 0.218 | 0.151 | − 0.282 | 0.019* | − 0.348 | 0.006*† |
| Sticky saliva during night | − 0.299 | 0.044* | − 0.192 | 0.115 | − 0.128 | 0.331 |
| Sticking saliva total score | − 0.271 | 0.072 | − 0.274 | 0.023* | − 0.256 | 0.048* |
M0 before treatment, M3 3 months after treatment, M6 6 months after treatment
*p ≤ 0.05
†p ≤ 0.006 (Bonferroni correction)